Mechanism and regulation of transcriptional elongation and termination by RNA polymerase II

Current Opinion in Genetics and Development

Volumn 7, Issue 2, 1997, Pages 199-204

  Shilatifard, Ali ^a   Conaway, Joan Weliky ^a,b   Conaway, Ronald C ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR; RNA POLYMERASE II;

ARTICLE; DROSOPHILA; EMBRYO; HUMAN; MESSENGER RNA SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RNA BINDING; RNA STRUCTURE; TRANSCRIPTION REGULATION; XENOPUS;

EID: 0030989229     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(97)80129-3     Document Type: Article

References (52)

1. Bentley DL: Regulation of transcriptional elongation by RNA polymerase II. Curr Opin Genet Dev 1995, 5:210-216.
2. Aso T, Conaway JW, Conaway RC: The RNA polymerase II elongation complex. FASEB J 1995, 9:1419-1428.
3. Reines D, Conaway JW, Conaway RC: The RNA polymerase II general elongation factors. Trends Biochem Sci 1996, 21:351-355.
4. Lis J, Wu C: Protein traffic on the heat shock promoter: parking, stalling, and trucking along. Cell 1993, 74:1-4.
5. Krumm A, Meulia T, Groudine M: Common mechanisms for the control eukaryotic transcriptional elongation. Bioessays 1993, 15:659-665.
6. O'Brien T, Hardin S, Greenleaf A, Lis JT: Phosphorylation of RNA polymerase II C-terminal domain and transcriptional elongation. Nature 1994, 370:75-77.
7. Brown SA, Imbalzano AN, Kingston RE: Activator-dependent regulation of transcriptional pausing on nucleosomal templates. Genes Dev 1996, 10:1479-1490. Promoter-proximal pausing by pol II and activator-dependent release of pol II from pausing is reconstituted for the first time in a cell-free system. Extended pausing by pol II downstream of the human hsp70 promoter is found to require the presence of nucleosomes on the DNA template. Release of pol II from pausing is shown to depend on the transcriptional activation domain of HSF1 and to require ATP and a fraction containing the SWI/ SNF complex, suggesting that chromatin remodelling may be a major step in the activator-dependent regulation of elongation. The assays described in this paper provide an excellent starting point for the biochemical characterization of promoter-proximal pausing and the mechanisms by which activators regulate this process.
8. Yankulov K, Blau J, Purton T, Roberts S, Bentley DL: Transcriptional elongation by RNA polymerase II is stimulated by transactivators. Cell 1994. 77:749-759.
9. Krumm A, Hickey LB, Groudine M: Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes Dev 1995, 9:559-572. These papers by Yankulov et al. [8] and Krumm et al. [9*] provide direct demonstrations that DNA-binding transactivators can promote elongation by pol II. These findings have forced a reappraisal of the roles of DNA-binding transactivators in gene expression and they have opened up a new area of research on elongation by pol II.
10. Blau J, Xiao H, McCracken S, O'Hare P, Greenblatt J, Bentley D: Three functional classes of transcriptional activation domains. Mol Cell Biol 1996, 15:2044-2055. In this paper, the authors make the striking discovery that DNA-binding transactivators fall into several functional classes, on the basis of on their abilities to stimulate initiation, elongation, or both stages of transcription. These findings provide important insight into the nature of DNA-binding transactivators and how they function in the regulation of eukaryotic gene expression.
11. Yankulov KY, Pandes M, McCracken S, Bouchard D, Bentlsy DL: TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes. Mol Cell Biol 1996, 16:3291-3299. Evidence implicating TFIIH in the regulation of elongation by pol II is presented. Anti-TFIIH antibodies are shown to inhibit activator-dependent elongation by pol II when microinjected into Xenopus oocytes, raising the possibility that activators target TFIIH to the pol II elongation complex.
12. Akhtar A, Faye G, Bentley DL: Distinct activated and non-activated RNA polymerase II complexes in yeast. EMBO J 1996, 15:4654-4664. Evidence supporting roles in elongation for the pol II CTD, for TFIIH, and for components of the pol II holoenzyme is presented. Mutations in the pol II CTD, kin28, the CTD kinase subunit of TFIIH, and SRB2, a component of the mediator and pol II holoenzyme are shown to impair activator-dependent stimulation of elongation in yeast cells.
13. Edwards AM, Kane CM, Young RA, Kornberg RD: Two dissociable subunits of yeast RNA polymerase II stimulate the initiation of transcription at a promoter in vitro. J Biol Chem 1991, 266:71-75.
14. Jones KA Peterlin BM: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994, 63:717-743.
15. Zhou Q, Sharp PA: Novel mechanism and factor for regulation by HIV-1 Tat. EMBO J 1895, 14:321-328. Fractionation of HeLa cell extracts that support Tat-dependent transcription led to the identification and partial purification of a Tat co-activator. In addition, Tat activation of elongation by pol II is shown not to require TAFs.
16. Zhou Q, Sharp PA: Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 1993, 274:605-610. A Tat co-activator, Tat-SF1, is purified from HeLa cells by Tat affinity chromatography and a cDNA that encodes it is isolated and characterized. TatSF1 contains RNA-binding motifs and is distantly related to the Ewing's sarcoma protein (EWS). Evidence that Tat-SF1 is associated in cells with a protein kinase is presented.
17. Wu F, Garcia J, Sigman D, Gaynor R: Tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev 1991, 5:2128-2140.
18. Sheline CT, Milocco LH, Jones KA: Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. Genes Dev 1991, 5:2508-5520.
19. Wu-Baer F, Sigman D, Gaynor RB: Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region of RNA is regulated by cellular factors and Tat. Proc Natl Acad Sci USA 1995, 92:7153-7157.
20. Wu-Baer F, Lane WS, Gaynor RB: Identification of a group of cellular cofactors that stimulate the binding of RNA polymerase II and TRP-185 to human immunodeficiency virus 1 RNA. J Biol Chem 1996, 271:4201-4208.
21. Okamoto H, Sheline CT, Corden JL, Jones KA, Peterlin BM: Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc Natl Acad Sci USA 1996, 93:11575-11579. See annotation [22*].
22. Chun RF, Jeang KT: Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1. J Biol Chem 1995, 271:27388-27894. These papers by Okamoto et al. [21*] and Chun and Jeang [22*] present evidence that the pol II CTD is required for Tat-dependent elongation in cells.
23. Herrman CH, Rice AP: Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995, 69:1612-1620. This paper presents evidence that Tat interacts with a DRB-sensitive CTD kinase. This finding provides the first direct evidence for a connection between Tat function and CTD kinase and has motivated subsequent investigations of the role of CTD phosphorylation in release of pol II from promoter-proximal pausing at the HIV promoter.
24. Aso T, Shilatifard A, Conaway JW, Conaway RC: Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease. J Clin Invest 1996, 97:1561-1569.
25. Fraser NW, Sehgal PB, Darnell JE: DRB-induced premature termination of late adenovirus transcription. Nature 1978, 272:590-593.
26. Chodosh LA, Fire A, Samuels M, Sharp PA: 5,6-Dichloro-1-β-dribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. J Biol Chem 1989, 264:2250-2257.
27. Marshall NF, Price DH: Control of formation of two distinct classes of RNA polymerase II elongation complexes. Mol Cell Biol 1992, 12:2076-2090.
28. Marshall NF, Price DH: Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem 1995, 270:12335-12338.
29. Marshall NF, Peng J, Xie Z, Price DH: Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem 1996, 271:27176-27183. In this elegant study, P-TEFb is shown to be a CTD kinase and the CTD is shown to be required for P-TEFb-dependent stimulation of pol II elongation in vitro. These findings provide the first direct biochemical evidence that elongation by pol II can be controlled by a CTD kinase and they provide a working model for the mechanism of DRB-induced arrest, a long-standing issue in studies of transcriptioral regulation.
30. Samkurashvili I, Luse DS: Translocation and transcriptional arrest during transcript elongation by RNA polymerase II. J Biol Chem 1996, 271:23495-23505.
31. Reeder TC, Hawley DK: Promoter-proximal sequences modulate RNA polymerase II elongation by a novel mechanism. Cell 1996, 87:767-777. The authors provide an explanation for the observation that the AdML major ate arrest site blocks transcription by pol II in vitro when located downstream of the AdML promoter but not of the mouse β-globin promoter. Hybridization of an anti-arrest element at the 5́ end of the β-globin transcript or small anti-sense RNA or DNA oligonucleotides to the nascent transcript upstream of the arrest site is shown to block arrest, leading to the proposal that hybridization of the anti-arrest element to the nascent transcript blocks a pol II conformational change that occurs upon arrest and that involves retraction of the nascent transcript into the interior of pol II.
32. Gu W, Powell W, Mote J, Reines D: Nascent RNA cleavage by arrested RNA polymerase II does not require upstream translocation of the elongation complex on DNA. J Biol Chem 1993, 268:25604-25616.
33. Gu W, Wind M, Reines D: Increased accomodation of nascent RNA in a product site on RNA polymerase 11 during arrest Proc Natl Acad Sci USA 1996, 93:6935-6940. This paper is an investigation of the fate of nascent pol II transcripts during SII-responsive arrest and demonstrates that the length of transcripts protected from RNase digestion by the pol II elongation complex increases dramatically upon arrest.
34. Chamberlin MJ: New models for the mechanism of transcription elongation and its regulation. Harvey Lectures 1995, 88:1-21.
35. Gu W, Reines D: Identification of a decay in transcription potential that results in elongation factor dependence of RNA polymerase II. J Biol Chem 1995, 270:11238-11244. This paper presents evidence that arrest by pol II is a time-dependent process that is antagonized by TFIIF. Interaction of TFIIF with elongating pol II decreases the likelihood that the enzyme will suffer arrest upon encountering an SII-responsive arrest site. Thus SII and TFIIF appear to control elongation by pol II in different yet complementary ways: whereas TFIIF decreases the duration of pausing by pol II and protects the elongation complex from arrest, SII reactivates elongation complexes that have arrested.
36. Takagi Y, Conaway JW, Conaway RC: A novel activity associated with RNA polymerase II elongation factor SIII: SIII directs promoter-independent transcription initiation by RNA polymerase II in the absence of initiation factors. J Biol Chem 1995, 270:24300-24305. Elongin (SIII) is shown to promote template-directed extension of 3′ hydroxyl termini of DNA fragments by pol II, raising the possibility that Elongin may stimulate elongation at least in part by promoting proper binding of the pol II catalytic site to the 3′ end of the nascent transcript.
37. Aso T, Lane WS, Conaway JW, Conaway RC: Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995, 269:1439-1443. In this paper, the Elongin (SIII) complex is shown to be the first pol II elongation factor with an inducible elongation activation domain The -110kDa Elongin A subunit is shown to contain the elongation activation domain and the -18kDa Elongin B and -15kDa Elongin C subunits are shown to form a stable binary complex that functions as a potent inducer of Elongin A transcriptional activity.
38. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995, 269:1402-1406. See annotation [39*].
39. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995, 269:1444-1446. These papers by Duan et al. [38*] and Kibel et al. [39*] present evidence that the Elongin BC complex is a potential target for regulation by the product of the von Hippel-Lindau (VHL) tumor suppressor gene. The VHL protein is shown to bind specifically to the Elongin BC complex both in vitro and in vivo. In addition, several VHL mutants found in tumors are shown to be defective in their abilities to bind to the Elongin BC complex, supporting a role for the VHL-Elongin BC interaction in VHL tumor-suppressor activity.
40. Aso T. Haque D, Barstead RJ, Conaway RC, Conaway JW: The inducible elongin A elongation activation domain: structure, function, and interaction with the elongin BC complex. EMBO J 1996, 15:5557-5566. In this report, the inducible Elongin A elongation activation domain is characterized. Its Elongin BC binding site is identified and shown to be similar to the Elongin BC binding site of the VHL protein.
41. Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD: Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 1996, 93:1770-1775. This paper presents evidence that the subcellular localization of the VHL protein is regulated by cell-cell contact. The VHL protein is shown to reside in the cytoplasm of confluent cultured cells and in the nucleus of sparse cells. These findings suggest that the VHL protein may perform its tumor- suppression function as a component of a signalling pathway regulated by cell density.
42. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996, 93:10595-10599. See annotation [44*].
43. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassillou E, Oldfield EH, Klausner RD, Linehan WM: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996, 93:10539-10594. See annotation [44*].
44. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny Baron G, Marme D: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996, 56:2299-2301. These papers by Iliopoulos et al. [42*], Gnarra et al. [43*], and Siemeister et al. [44*] report that expression of the VEGF gene is mis-regulated and constitutive in cells lacking a functional VHL protein. In addition, Iliopoulos et al. [42*] and Gnarra et al. [43*] propose that the VHL protein may have a role in regulating VEGF mRNA turnover, on the basis of findings indicating that, first, in transient transfection assays, reporter gene expression controlled by VEGF upstream sequences is similar in cells containing wild-type or mutant VHL genes; second, that pol II density on the endogenous VEGF gene, as measured by nuclear run-on assays, is similar in cells containing wild-type or mutant VHL genes; and third, that VEGF mRNA stability appears to be increased in one of several VHL mutant cell lines examined.
45. Shilatifard A, Lane WS, Jackson KW, Conaway RC, Conaway JW: The human ELL gene encodes a novel RNA polymerase II elongation factor. Science 1996, 271:1673-1876. The authors of this paper describe the identification of a novel pol II elongation factor and demonstrate that it is encoded by the human ELL gene, which is a frequent target for translocations in acute myeloid leukemia. Taken together with evidence for a possible role of Elongin in the VHL familial cancer predisposition syndrome, this study provides the second potential link between transcription elongation and oncogenesis.
46. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD: Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci USA 1984, 91:12110-12114.
47. Mitani K, Kanda Y, Ogawa S, Tanaka T, Inazawa J, Yazaki Y, Hirai H: Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood 1995, 85:2017-2024.
48. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie ANJ, King G, Rabbitts TH: An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996, 85:353-861.
49. Wahle E, Keller W: The biochemistry of 3′-end cleavage and polyadenylation of messenger RNA precursors. Annu Rev Biochem 1992, 61:419-440.
50. Xie Z, Price DH: Purification of an RNA polymerase II transcript release factor from Drosophila. J Biol Chem 1996, 271:11043-11046. Description of the purification of Factor 2, a candidate eukaryotic termination activity. Factor 2 is a 154kDa protein that interacts with the pol II ternary elongation complex and induces ATP-dependent release of nascent transcripts.
51. Richardson JP: Structural organization of transcription termination factor rho. J Biol Chem 1996, 271:1251-1254.
52. Selby CP, Sancar A: Molecular mechanism of transcription repair coupling. Science 1693, 260:53-58.